Butt, Thomas; Patel, Praveen; Tufail, Adnan; Rubin, Gary - In: Applied Health Economics and Health Policy 12 (2014) 3, pp. 289-297
There is considerable structural uncertainty associated with the choice of outcome for modelling the cost effectiveness of AMD treatments. Bevacizumab has a higher incremental QALY gain and more favourable incremental cost-effectiveness ratio when cost effectiveness is assessed using contrast...